Department of Dermatology, Haukeland University Hospital, Bergen, Norway; Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Scand J Immunol. 2013 Sep;78(3):291-7. doi: 10.1111/sji.12084.
Renal transplant recipients (RTR) have a high risk of tumour development, especially cutaneous squamous cell carcinomas (SCC), due to long-term immunosuppressive therapy. RTR may develop multiple lesions over short time periods, and these are often more aggressive with a higher risk of local recurrence and metastasis resulting in increased morbidity and mortality in these patients. Therefore, we took the first step towards evaluating the possibility of generating a therapeutic vaccine based on monocyte-derived dendritic cells (moDC) for these patients. We analysed the phenotype and cytokine/chemokine profile of moDC from long-term immunosuppressed RTR with and without previous SCC. The number of peripheral blood mononuclear cells (PBMC) isolated per ml blood as well as the efficiency of generating moDC from peripheral blood mononuclear cells (PBMC) was similar in patients and immunocompetent controls. Phenotype and cytokine/chemokine profile of the moDC from immunosuppressed patients were similar to those from immunocompetent controls, making moDC-based immunotherapy a potential future treatment option for RTR with multiple SCC.
肾移植受者（RTR）由于长期免疫抑制治疗，患肿瘤的风险很高，特别是皮肤鳞状细胞癌（SCC）。RTR 可能在短时间内出现多个病变，这些病变往往更具侵袭性，局部复发和转移的风险更高，导致这些患者的发病率和死亡率增加。因此，我们朝着为这些患者开发基于单核细胞衍生树突状细胞（moDC）的治疗性疫苗的方向迈出了第一步。我们分析了长期免疫抑制的 RTR 中有无 SCC 病史的 moDC 的表型和细胞因子/趋化因子谱。从外周血单个核细胞（PBMC）中分离出的每毫升血液中的外周血单个核细胞（PBMC）数量以及从外周血单个核细胞（PBMC）生成 moDC 的效率在患者和免疫功能正常的对照组中相似。来自免疫抑制患者的 moDC 的表型和细胞因子/趋化因子谱与免疫功能正常的对照组相似，这使得基于 moDC 的免疫疗法成为治疗多发性 SCC 的 RTR 的一种潜在未来治疗选择。
